stoxline Quote Chart Rank Option Currency Glossary
  
Ampio Pharmaceuticals, Inc. (AMPE)
1.68  0.05 (3.07%)    03-18 15:59
Open: 1.62
High: 1.68
Volume: 33,454
  
Pre. Close: 1.63
Low: 1.6
Market Cap: 1(M)
Technical analysis
2024-03-18 4:42:09 PM
Short term     
Mid term     
Targets 6-month :  2.45 1-year :  2.88
Resists First :  2.09 Second :  2.47
Pivot price 1.69
Supports First :  1.5 Second :  1.24
MAs MA(5) :  1.66 MA(20) :  1.72
MA(100) :  2.08 MA(250) :  3.51
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  15.4 D(3) :  16.2
RSI RSI(14): 48.2
52-week High :  8.19 Low :  1.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ AMPE ] has closed above bottom band by 48.6%. Bollinger Bands are 37.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.68 - 1.7 1.7 - 1.71
Low: 1.57 - 1.59 1.59 - 1.6
Close: 1.66 - 1.68 1.68 - 1.7
Company Description

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

Headline News

Tue, 12 Mar 2024
Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.com - Defense World

Mon, 11 Mar 2024
Ampio Pharmaceuticals Inc (AMPE) Stock Gains 12.03% This Week: Is It a Good Pick? - InvestorsObserver

Fri, 01 Mar 2024
Should You Sell Ampio Pharmaceuticals Inc (AMPE) Stock Friday? - InvestorsObserver

Thu, 29 Feb 2024
How Will the Market React to Ampio Pharmaceuticals Inc (AMPE) Stock Getting a Bullish Rating - InvestorsObserver

Sun, 25 Feb 2024
Ampio Pharmaceuticals (NYSE:AMPE) Now Covered by Analysts at StockNews.com - Defense World

Thu, 15 Feb 2024
Ampio Pharmaceuticals Announces Nonclinical Study Success - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 2.1 (%)
Held by Institutions 0.3 (%)
Shares Short 35 (K)
Shares Short P.Month 41 (K)
Stock Financials
EPS -11.7
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.67
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -47.3 %
Return on Equity (ttm) -91.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -11.65
Qtrly Earnings Growth 0 %
Operating Cash Flow -11 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio -0.15
PEG Ratio 0
Price to Book value 0.25
Price to Sales 0
Price to Cash Flow -0.14
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android